Stigma and Depression Hinder Mental Healthcare Access for Opioid Users

Depression and the fear of being judged may be quietly cutting off people who use opioids from mental health care—not only by dampening their motivation to seek help, but by leaving them unsure where to go in the first place. That is the central finding of a new study published in Community Mental Health Journal, which suggests that knowing how to navigate the mental healthcare system is itself a barrier shaped by emotional and social forces.

The research, led by Antoine Khati and Roman Shrestha of the Department of Allied Health Sciences at the University of Connecticut, together with colleagues at Yale University, analyzed survey data from 199 people who use opioids (PWUO) in New Haven, Connecticut. The team set out to answer a deceptively simple question: are depressive symptoms and anticipated stigma—the worry about what others might think, say, or do if one seeks help—associated with not knowing where to obtain mental health care?

The answer, in both cases, was a resounding yes. Nearly 59 percent of participants screened positive for depressive symptoms using the PHQ-9, a widely validated nine-item instrument with a cutoff score of 10 or higher indicating probable major depression. Those who screened positive had roughly four times higher odds of reporting that they were “unsure where to go to get mental healthcare” compared with those below the threshold, after adjusting for demographic and other covariates (adjusted odds ratio = 4.00; 95% confidence interval: 2.10–7.88). Participants who identified concern about others’ reactions as a barrier to seeking help fared even worse on this measure: they had more than five times the odds of reporting the navigation knowledge barrier (aOR = 5.16; 95% CI: 2.75–10.00).

Crucially, when the researchers entered both factors into a single jointly adjusted model, each remained independently associated with the outcome. Depressive symptoms carried an adjusted odds ratio of 3.50 (95% CI: 1.77–7.15), while anticipated stigma carried an adjusted odds ratio of 4.67 (95% CI: 2.43–9.26). In other words, neither depression nor stigma simply absorbed the other’s effect; both appear to operate through distinct pathways that converge on the same practical problem—people simply do not know where to turn.

The researchers also tested whether the two factors interacted, asking whether stigma might amplify the effect of depression, or vice versa. The interaction term approached, but did not reach, conventional statistical significance (p = 0.052). The authors are careful on this point: while the joint model shows independent effects, the near-significant interaction hints that the combination of high depressive burden and high anticipated stigma may be especially corrosive—though larger samples would be needed to confirm it.

The logic behind these associations is grounded in how people actually learn about mental health services. Information about where to find care is rarely acquired through directories or brochures alone. It typically flows through social transactions: disclosing distress to a friend, describing symptoms to a physician, or asking a caseworker for a referral. Each of these transactions requires disclosure, and each disclosure carries risk. For someone worried about judgment—whether from family, peers, employers, or providers themselves—the calculus may favor silence. And silence, in turn, forecloses the very conversations through which navigation knowledge is transmitted.

Depression adds its own mechanism. The cognitive and motivational symptoms of depression—anhedonia, fatigue, hopelessness, and impaired executive function—can make the already daunting task of identifying, contacting, and enrolling in services feel insurmountable. Prior research has documented high rates of psychiatric comorbidity among people with opioid use disorder, and meta-analytic work has shown that mental disorders are markedly prevalent in this population. Yet co-occurring depression and substance use often lead to poorer engagement with treatment, and individuals with both conditions are less likely to receive adequate depression care. The new study extends this literature by focusing not on treatment uptake, which has been studied extensively, but on a more upstream variable: whether a person even knows where care could be obtained.

The conceptual framing draws on established stigma theory. Anticipated stigma—the expectation of discrimination or devaluation before it occurs—has been shown in longitudinal work to reduce mental health service use, distinct from internalized stigma, in which negative stereotypes are turned inward. The broader Health Stigma and Discrimination Framework positions stigma as a cross-cutting force operating at individual, interpersonal, and structural levels. In the opioid context, stigma is widely regarded as a fundamental hindrance to responding to the overdose crisis, with nationally representative surveys documenting pervasive negative social attitudes toward people with opioid use disorder. Studies among patients in opioid substitution treatment in Sweden and among people navigating opioid treatment in Tanzania have similarly documented perceived healthcare stigma as a barrier to engagement.

What makes the new findings distinctive is the focus on navigation knowledge as an outcome in its own right. Much of the existing literature treats stigma and depression as barriers to the decision to seek care. This study suggests they may also be barriers to the capacity to seek care—degrading the informational foundation on which any help-seeking attempt must rest. A person who is both depressed and afraid of judgment may never accumulate the practical knowledge—clinic locations, eligibility criteria, insurance requirements, appointment procedures—that navigating a fragmented behavioral health system demands.

The cross-sectional design imposes limits. The data cannot establish whether depression and stigma cause navigation deficits, whether lacking knowledge of services deepens depression and reinforces stigma, or whether some third factor—such as social isolation or poverty—drives all three. The measurement also relied on two single-item barrier indicators drawn from validated barrier instruments, which is efficient but coarse. And the sample, recruited in a single Connecticut city, may not generalize to rural areas or other regions. Nonetheless, the strength and consistency of the associations—odds ratios of three to five across models—are difficult to dismiss as statistical noise.

The implications for practice are concrete. The authors argue that improving mental healthcare access for PWUO requires attention to both depressive symptoms and anticipated stigma, alongside practical navigation and linkage supports embedded in harm reduction and substance use treatment settings. In practical terms, that could mean universal depression screening in syringe service programs and opioid treatment programs, with proactive referral rather than passive advice; stigma-reduction training for staff at the points where PWUO already interact with the system; and peer navigation models in which trained peers with lived experience supply the logistical knowledge that disclosure-dependent channels fail to deliver. Evidence from intervention research on mental health stigma reduction suggests that contact-based and educational approaches can shift attitudes, though structural change remains the harder frontier.

There is also a message embedded in the numbers about where the burden lies. With nearly six in ten participants screening positive for depressive symptoms, the study population reflects a clinical reality well documented in the literature: depression is not a marginal comorbidity in this group but a dominant one. Any mental healthcare strategy that ignores this comorbidity—or that assumes people will find their way to services once motivated—misses the dual lock that depression and stigma place on the front door of the system.

The study was partially supported by career development awards from the National Institute on Drug Abuse (K01 DA051346 to Dr. Shrestha and K24 DA051344 to Dr. Copenhaver). The funding agency had no role in the study design, data collection, analysis, or the decision to submit the manuscript for publication. The authors declare no competing interests. The article, received in July 2025 and published on 18 July 2026, reflects a growing recognition in community mental health research that the pathway into care begins long before the first appointment—and that for people who use opioids, the road may be blocked at the very first signpost.